Trade

with

Anthera Pharmaceuticals Inc
(NASDAQ: ANTH)
AdChoices
1.92
+0.03
+1.32%
After Hours :
-
-
-

Open

1.93

Previous Close

1.90

Volume (Avg)

70.48k (187.60k)

Day's Range

1.88-2.00

52Wk Range

1.53-3.79

Market Cap.

43.04M

Dividend Rate ( Yield )

-

Beta

1.54

Shares Outstanding

22.71M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 0

    • Net Income

    • -30.86M

    • Market Cap.

    • 43.04M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.54

    • Forward P/E

    • -

    • Price/Sales

    • -

    • Price/Book Value

    • 4.12

    • Price/Cash flow

    • -1.50

      • EBITDA

      • -27.91M

      • Return on Capital %

      • -81.24

      • Return on Equity %

      • -158.57

      • Return on Assets %

      • -81.24

      • Book Value/Share

      • 0.46

      • Shares Outstanding

      • 22.71M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 24.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -2.00

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 69.92

            • Pre-Tax Margin

            • -

            • 21.84

            • Net Profit Margin

            • -

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.54

              • 0.32

              • Current Ratio

              • 2.68

              • 1.92

              • Quick Ratio

              • 2.62

              • 1.31

              • Interest Coverage

              • -24.31

              • 17.64

              • Leverage Ratio

              • 2.30

              • 2.03

              • Book Value/Share

              • 0.46

              • 14.62

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.26

                • 22.99

                • P/E Ratio 5-Year High

                • -48.20

                • 193.96

                • P/E Ratio 5-Year Low

                • -1.02

                • 87.26

                • Price/Sales Ratio

                • -

                • 3.84

                • Price/Book Value

                • 4.12

                • 3.83

                • Price/Cash Flow Ratio

                • -1.50

                • 14.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -158.57

                    (-)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • -81.24

                    (-130.20)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • -88.21

                    (-)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • -

                  • 90.07k

                  • Inventory Turnover

                  • -

                  • 2.46

                  • Asset Turnover

                  • -

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -28.25M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.50
                  Ownership

                  Institutional Ownership

                  54.74%

                  Top 10 Institutions

                  42.92%

                  Mutual Fund Ownership

                  9.84%

                  Float

                  96.47%

                  5% / Insider Ownership

                  3.30%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Biotechnology Discovery

                  •  

                    671,850

                  • 29.51

                  • 3.28

                  • Rhenman Healthcare Eq L/S

                  •  

                    300,000

                  • 42.86

                  • 1.32

                  • Franklin Biotechnology Discovery Fund

                  •  

                    292,062

                  • 0.00

                  • 1.29

                  • Vanguard Total Stock Mkt Idx

                  •  

                    283,343

                  • 0.00

                  • 1.25

                  • Vanguard Extended Market Index Fund

                  •  

                    135,113

                  • 3.22

                  • 0.59

                  • FCP OP MEDICAL BioHealthTrends

                  •  

                    133,932

                  • 0.00

                  • 0.58

                  • Vanguard Instl Total Stock Market Index

                  •  

                    110,168

                  • 0.00

                  • 0.49

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    86,499

                  • 0.00

                  • 0.38

                  • APO Medical Opportunities

                  •  

                    64,182

                  • 0.00

                  • 0.27

                  • RHO Investments SIL

                  •  

                    36,984

                  • -0.08

                  • 0.19

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Deerfield Management Co

                  •  

                    1,691,857

                  • 0.00%

                  • 7.47

                  • Great Point Partners LLC

                  •  

                    1,500,000

                  • +9.55%

                  • 6.62

                  • Franklin Advisers, Inc.

                  •  

                    963,912

                  • +18.88%

                  • 4.26

                  • Orbimed Advisors, LLC

                  •  

                    851,750

                  • -8.68%

                  • 3.76

                  • Bvf Inc

                  •  

                    559,624

                  • 0.00%

                  • 2.47

                  • Perceptive Advisors LLC

                  •  

                    478,456

                  • 0.00%

                  • 2.11

                  • Vanguard Group, Inc.

                  •  

                    470,946

                  • +10.02%

                  • 2.08

                  • Sabby Management LLC

                  •  

                    448,000

                  • -34.89%

                  • 1.98

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Distressed

                  Style

                  Small Growth

                  Anthera Pharmaceuticals, Inc., was incorporated on September 9, 2004 in the state of Delaware. It is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflamm...moreation and autoimmune diseases. The Company’s product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells. Its product developme...morent program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which it believes current treatments are either inadequate or non-existent. It currently relies on contract manufacturers to produce drug substances and drug products required for its clinical studies under current Good Manufacturing Practice with oversight by its internal managers. The Company competes with pharmaceutical and more established biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.lessless

                  Key People

                  Paul F. Truex

                  CEO/Director/President

                  Dr. Christopher S. Henney, PhD

                  Chairman of the Board/Director

                  Steven B. Engle

                  Director

                  Mr. Brian R. Mueller

                  Director

                  Dr. Philip T. Sager, M.D.

                  Director

                  • Anthera Pharmaceuticals Inc

                  • 25801 Industrial Boulevard

                  • Hayward, CA 94545

                  • USA.Map

                  • Phone: +1 510 856-5600

                  • Fax: +1 510 856-5597

                  • anthera.com

                  Incorporated

                  2004

                  Employees

                  25

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: